Gamida Cell Ltd (GMDAQ)

[midastouch017]

Q- to IR:

Do you know if GMDA is entitled to PRV -Priority Review Voucher? its worth $100-250M ?

A-

Because omidubicel has Breakthrough Therapy Designation and based on the strength of the Phase 3 data, we anticipate a priority review.

Just please stress that this is our hope and expectation based on what we know to date (Breakthrough Designation, strong topline data) – but that it is not a guarantee and the FDA will make its own assessment once the BLA is submitted.